ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by ADMA Biologics, Inc. on March 9, 2022, reporting events that occurred on March 7, 2022. The filing focuses on Item 5.02 regarding the appointment of certain officers and their compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It details specific executive compensation figures approved by the Board of Directors:
- Adam S. Grossman (CEO): 2022 Base Salary of $636,540; 2021 Cash Bonus of $506,142; 300,000 RSUs; 600,000 Stock Options.
- Brian Lenz (CFO): 2022 Base Salary of $445,578; 2021 Cash Bonus of $245,284; 137,500 RSUs; 275,000 Stock Options; Other Compensation of $120,000.
Material Changes
The primary material change is the approval of 2022 base salaries and the award of 2021 performance-based cash bonuses and equity incentives. The cash bonuses reflect the achievement of 126% of the Company's 2021 corporate goals and milestones.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, outlook, or discussion of risks and contingencies. It notes that the compensation awards were determined in consultation with an independent compensation consultant and approved by the Board based on performance evaluations.
Investor Verification Points
- Verify the vesting schedules for the granted RSUs (quarterly over four years) and stock options (25% at one year, remainder monthly over three years).
- Confirm the exercise price of the stock options is $1.67 per share, based on the March 7, 2022 closing price.
- Note the "Other Compensation" for the CFO includes $5,000 per month in temporary living expenses plus tax gross-up through December 31, 2022.
- Review the 2014 Omnibus Incentive Compensation Plan for full terms of the equity awards.